J Behr, C Vogelmeier, T Beinert, M Meurer, F Krombach, G Konig and G Fruhmann
Department of Internal Medicine I, Klinikum Grosshadern, University of Munich, Germany.

Fibrosing alveolitis (FA) is a frequent and often fatal complication of systemic sclerosis (SSC). Alveolar inflammation has been recognized as a primary event in the pulmonary manifestation of SSC. To evaluate the significance of the alveolitis in SSC, we performed bronchoalveolar lavage (BAL) and correlated the generated data with changes in lung function over time. Seventy nine SSC patients with pulmonary involvement were followed for 56.8 +/- 3.1 wk (mean +/- SEM) with a repeat lung function test at the end of the follow-up period. During follow-up, 38 patients were treated with a systemic immunosuppressive regimen. For evaluation, patients were assigned to two groups according to whether their BAL cell differential was normal (inactive BAL) or abnormal (active BAL: i.e., polymorphonuclear leukocytes > 5% and/or lymphocytes > 15%). Active BAL was associated with more severe lung function impairment than was inactive BAL, and patients with active BAL deteriorated during follow-up if untreated. In contrast, treated patients with active BAL stabilized or improved. In summary, active alveolitis as characterized by BAL is associated with progressive pulmonary disease in SSC patients, and a significant positive effect of immunosuppressive therapy on the course of pulmonary disease was observed in patients with active BAL.

This article has been cited by other articles:

				C. Strange and J. R. Seibold Scleroderma Lung Disease: "If You Don't Know Where You Are Going, Any Road Will Take You There" Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1178 - 1179. [Full Text] [PDF]

				C. Strange, M. B. Bolster, M. D. Roth, R. M. Silver, A. Theodore, J. Goldin, P. Clements, J. Chung, R. M. Elashoff, R. Suh, et al. Bronchoalveolar Lavage and Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 91 - 98. [Abstract] [Full Text] [PDF]

				D. P. Tashkin, R. Elashoff, P. J. Clements, M. D. Roth, D. E. Furst, R. M. Silver, J. Goldin, E. Arriola, C. Strange, M. B. Bolster, et al. Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease Am. J. Respir. Crit. Care Med., November 15, 2007; 176(10): 1026 - 1034. [Abstract] [Full Text] [PDF]

				A. BEREZNE, D. VALEYRE, B. RANQUE, L. GUILLEVIN, and L. MOUTHON Interstitial Lung Disease Associated with Systemic Sclerosis: What Is the Evidence for Efficacy of Cyclophosphamide? Ann. N.Y. Acad. Sci., September 1, 2007; 1110(1): 271 - 284. [Abstract] [Full Text] [PDF]

				K. P. Tiev, J. Cabane, F. Aubourg, A. Kettaneh, M. Ziani, L. Mouthon, S. Duong-Quy, I. Fajac, L. Guillevin, and A. T. Dinh-Xuan Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide Eur. Respir. J., July 1, 2007; 30(1): 26 - 30. [Abstract] [Full Text] [PDF]

				D. P. Tashkin, R. Elashoff, P. J. Clements, J. Goldin, M. D. Roth, D. E. Furst, E. Arriola, R. Silver, C. Strange, M. Bolster, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med., June 22, 2006; 354(25): 2655 - 2666. [Abstract] [Full Text] [PDF]

				S. A. Papiris, A. Kollintza, P. Kitsanta, G. Kapotsis, M. Karatza, J. Milic-Emili, C. Roussos, and Z. Daniil Relationship of BAL and Lung Tissue CD4+ and CD8+ T Lymphocytes, and Their Ratio in Idiopathic Pulmonary Fibrosis Chest, October 1, 2005; 128(4): 2971 - 2977. [Abstract] [Full Text] [PDF]

				P. A. McSweeney, R. A. Nash, K. M. Sullivan, J. Storek, L. J. Crofford, R. Dansey, M. D. Mayes, K. T. McDonagh, J. L. Nelson, T. A. Gooley, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes Blood, August 13, 2002; 100(5): 1602 - 1610. [Abstract] [Full Text] [PDF]

				D. Bouros, A. U. Wells, A. G. Nicholson, T. V. Colby, V. Polychronopoulos, P. Pantelidis, P. L. Haslam, D. A. Vassilakis, C. M. Black, and R. M. du Bois Histopathologic Subsets of Fibrosing Alveolitis in Patients with Systemic Sclerosis and Their Relationship to Outcome Am. J. Respir. Crit. Care Med., June 15, 2002; 165(12): 1581 - 1586. [Abstract] [Full Text] [PDF]

				B. White, W. C. Moore, F. M. Wigley, H. Q. Xiao, and R. A. Wise Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis Ann Intern Med, June 20, 2000; 132(12): 947 - 954. [Abstract] [Full Text] [PDF]

				C. Witt, A. C Borges, M. John, I. Fietze, G. Baumann, and A. Krause Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis Ann Rheum Dis, October 1, 1999; 58(10): 635 - 640. [Abstract] [Full Text]

				D. M Mitchell and A. Woodcock Introduction Thorax, August 1, 1999; 54(90002): S1 - 1. [PDF]

				P. Paredi, S. A. Kharitonov, S. Loukides, P. Pantelidis, R. M. d. Bois, and P. J. Barnes Exhaled Nitric Oxide Is Increased in Active Fibrosing Alveolitis Chest, May 1, 1999; 115(5): 1352 - 1356. [Abstract] [Full Text] [PDF]

				P. MONTUSCHI, G. C. TONI, P. PAREDI, P. PANTELIDIS, R. M. du BOIS, S. A. KHARITONOV, and P. J. BARNES 8-Isoprostane as a Biomarker of Oxidative Stress in Interstitial Lung Diseases Am. J. Respir. Crit. Care Med., November 1, 1998; 158(5): 1524 - 1527. [Abstract] [Full Text] [PDF]

				J Behr, K Maier, B Degenkolb, F Krombach, and C Vogelmeier Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression Am. J. Respir. Crit. Care Med., December 1, 1997; 156(6): 1897 - 1901. [Abstract] [Full Text]

				B. T. SOCIETY and S. O. C. COMMITTEE The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults---British Thoracic Society recommendations Thorax, April 1, 1990; 54(90001): 1S - 28. [Full Text]